Clorox Co (NYSE:CLX) has been given an average rating of “Hold” by the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $147.25.
Several brokerages recently weighed in on CLX. Wells Fargo & Co increased their target price on Clorox from $145.00 to $160.00 and gave the company a “market perform” rating in a report on Wednesday, December 12th. They noted that the move was a valuation call. Zacks Investment Research cut Clorox from a “hold” rating to a “sell” rating in a report on Monday, December 3rd. Bank of America restated a “neutral” rating and set a $170.00 target price (up from $150.00) on shares of Clorox in a report on Thursday, December 6th. Citigroup increased their target price on Clorox from $153.00 to $169.00 and gave the company a “hold” rating in a report on Tuesday, November 20th. Finally, BMO Capital Markets set a $175.00 target price on Clorox and gave the company a “buy” rating in a report on Tuesday, February 5th.
In other Clorox news, SVP Matthew T. Laszlo sold 10,585 shares of the company’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total transaction of $1,628,925.65. Following the completion of the transaction, the senior vice president now owns 17,994 shares of the company’s stock, valued at approximately $2,769,096.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benno O. Dorer sold 152,449 shares of the company’s stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $164.83, for a total value of $25,128,168.67. Following the transaction, the chief executive officer now directly owns 111,735 shares of the company’s stock, valued at approximately $18,417,280.05. The disclosure for this sale can be found here. Insiders have sold a total of 256,728 shares of company stock valued at $41,973,324 in the last ninety days. 1.40% of the stock is currently owned by corporate insiders.
CLX stock traded up $0.47 during trading on Wednesday, hitting $155.37. 275,324 shares of the company traded hands, compared to its average volume of 1,239,115. The stock has a market capitalization of $19.95 billion, a PE ratio of 24.82, a P/E/G ratio of 3.86 and a beta of 0.29. Clorox has a 1 year low of $113.57 and a 1 year high of $167.70. The company has a debt-to-equity ratio of 3.08, a current ratio of 1.15 and a quick ratio of 0.66.
Clorox (NYSE:CLX) last issued its earnings results on Monday, February 4th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.08. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.47 billion. Clorox had a return on equity of 105.97% and a net margin of 12.65%. Clorox’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.77 EPS. Analysts anticipate that Clorox will post 6.33 EPS for the current year.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Further Reading: Straddles
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.